The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: Analysis of 32 cases

B. W. Corn, K. M. Greven, M. E. Randall, Aaron Wolfson, R. Y. Kim, R. M. Lanciano

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective: To determine the role of irradiation in the management of brain metastases from epithelial ovarian cancer. Methods: Tumor registries from five university cancer centers were searched to identify ovarian cancer patients with brain metastases. During a 30-year period (19651994), 4027 ovarian cancer patients were evaluated, 32 of whom were found to have cerebral metastases. Each received fractionated whole-brain irradiation (median dose 30 Gy, range 20-52.5). Five patients received concomitant chemotherapy with whole-brain irradiation. Results: The median survival time for the whole population was 4 months. For the entire series, symptomatic response (complete response and partial response) was achieved in 23, 16 of whom were palliated until death. Patients with higher Karnofsky performance status (70 or above versus below 70) were more likely to derive a palliative response and attained a statistically significant survival advantage. No other factor predicted the likelihood of deriving a palliative response or a survival advantage after treatment. Conclusions: In this large review of patients with cerebral metastases from ovarian cancer, we found that most of those treated with whole-brain irradiation achieved palliation until death. Nearly all women with high performance status derived durable palliation from cerebral irradiation. Whole-brain irradiation was an effective means of palliating ovarian cancer metastatic to the brain and provided a favorable alternative to other means of management.

Original languageEnglish
Pages (from-to)955-959
Number of pages5
JournalObstetrics and Gynecology
Volume86
Issue number6
DOIs
StatePublished - Dec 1 1995

Fingerprint

Cranial Irradiation
Ovarian Neoplasms
Brain
Neoplasm Metastasis
Survival
Karnofsky Performance Status
Registries
Neoplasms
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The efficacy of cranial irradiation in ovarian cancer metastatic to the brain : Analysis of 32 cases. / Corn, B. W.; Greven, K. M.; Randall, M. E.; Wolfson, Aaron; Kim, R. Y.; Lanciano, R. M.

In: Obstetrics and Gynecology, Vol. 86, No. 6, 01.12.1995, p. 955-959.

Research output: Contribution to journalArticle

Corn, B. W. ; Greven, K. M. ; Randall, M. E. ; Wolfson, Aaron ; Kim, R. Y. ; Lanciano, R. M. / The efficacy of cranial irradiation in ovarian cancer metastatic to the brain : Analysis of 32 cases. In: Obstetrics and Gynecology. 1995 ; Vol. 86, No. 6. pp. 955-959.
@article{5901d8f8cf024e3caa9f9a090565ee01,
title = "The efficacy of cranial irradiation in ovarian cancer metastatic to the brain: Analysis of 32 cases",
abstract = "Objective: To determine the role of irradiation in the management of brain metastases from epithelial ovarian cancer. Methods: Tumor registries from five university cancer centers were searched to identify ovarian cancer patients with brain metastases. During a 30-year period (19651994), 4027 ovarian cancer patients were evaluated, 32 of whom were found to have cerebral metastases. Each received fractionated whole-brain irradiation (median dose 30 Gy, range 20-52.5). Five patients received concomitant chemotherapy with whole-brain irradiation. Results: The median survival time for the whole population was 4 months. For the entire series, symptomatic response (complete response and partial response) was achieved in 23, 16 of whom were palliated until death. Patients with higher Karnofsky performance status (70 or above versus below 70) were more likely to derive a palliative response and attained a statistically significant survival advantage. No other factor predicted the likelihood of deriving a palliative response or a survival advantage after treatment. Conclusions: In this large review of patients with cerebral metastases from ovarian cancer, we found that most of those treated with whole-brain irradiation achieved palliation until death. Nearly all women with high performance status derived durable palliation from cerebral irradiation. Whole-brain irradiation was an effective means of palliating ovarian cancer metastatic to the brain and provided a favorable alternative to other means of management.",
author = "Corn, {B. W.} and Greven, {K. M.} and Randall, {M. E.} and Aaron Wolfson and Kim, {R. Y.} and Lanciano, {R. M.}",
year = "1995",
month = "12",
day = "1",
doi = "10.1016/0029-7844(95)00320-Q",
language = "English",
volume = "86",
pages = "955--959",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The efficacy of cranial irradiation in ovarian cancer metastatic to the brain

T2 - Analysis of 32 cases

AU - Corn, B. W.

AU - Greven, K. M.

AU - Randall, M. E.

AU - Wolfson, Aaron

AU - Kim, R. Y.

AU - Lanciano, R. M.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Objective: To determine the role of irradiation in the management of brain metastases from epithelial ovarian cancer. Methods: Tumor registries from five university cancer centers were searched to identify ovarian cancer patients with brain metastases. During a 30-year period (19651994), 4027 ovarian cancer patients were evaluated, 32 of whom were found to have cerebral metastases. Each received fractionated whole-brain irradiation (median dose 30 Gy, range 20-52.5). Five patients received concomitant chemotherapy with whole-brain irradiation. Results: The median survival time for the whole population was 4 months. For the entire series, symptomatic response (complete response and partial response) was achieved in 23, 16 of whom were palliated until death. Patients with higher Karnofsky performance status (70 or above versus below 70) were more likely to derive a palliative response and attained a statistically significant survival advantage. No other factor predicted the likelihood of deriving a palliative response or a survival advantage after treatment. Conclusions: In this large review of patients with cerebral metastases from ovarian cancer, we found that most of those treated with whole-brain irradiation achieved palliation until death. Nearly all women with high performance status derived durable palliation from cerebral irradiation. Whole-brain irradiation was an effective means of palliating ovarian cancer metastatic to the brain and provided a favorable alternative to other means of management.

AB - Objective: To determine the role of irradiation in the management of brain metastases from epithelial ovarian cancer. Methods: Tumor registries from five university cancer centers were searched to identify ovarian cancer patients with brain metastases. During a 30-year period (19651994), 4027 ovarian cancer patients were evaluated, 32 of whom were found to have cerebral metastases. Each received fractionated whole-brain irradiation (median dose 30 Gy, range 20-52.5). Five patients received concomitant chemotherapy with whole-brain irradiation. Results: The median survival time for the whole population was 4 months. For the entire series, symptomatic response (complete response and partial response) was achieved in 23, 16 of whom were palliated until death. Patients with higher Karnofsky performance status (70 or above versus below 70) were more likely to derive a palliative response and attained a statistically significant survival advantage. No other factor predicted the likelihood of deriving a palliative response or a survival advantage after treatment. Conclusions: In this large review of patients with cerebral metastases from ovarian cancer, we found that most of those treated with whole-brain irradiation achieved palliation until death. Nearly all women with high performance status derived durable palliation from cerebral irradiation. Whole-brain irradiation was an effective means of palliating ovarian cancer metastatic to the brain and provided a favorable alternative to other means of management.

UR - http://www.scopus.com/inward/record.url?scp=0029414544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029414544&partnerID=8YFLogxK

U2 - 10.1016/0029-7844(95)00320-Q

DO - 10.1016/0029-7844(95)00320-Q

M3 - Article

C2 - 7501347

AN - SCOPUS:0029414544

VL - 86

SP - 955

EP - 959

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -